Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.
CAS Number:
[2329669-72-7]
* VAT and and shipping costs not included. Errors and price changes excepted
